November 04, 2019
1 min read

Phase 3 trial of pancreatic cancer therapy misses primary endpoint

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

A phase 3 trial designed to assess an investigational drug for first-line treatment of metastatic pancreatic cancer failed to meet its primary endpoint of OS, according to the agent’s manufacturer.

Development of the agent — pegvorhyaluronidase alfa (PEGPH20, Halozyme Therapeutics) — will be discontinued.

Pegvorhyaluronidase alfa is the pegylated version of rHuPH20, Halozyme’s proprietary recombinant human hyaluronidase enzyme. rHuPH20 temporarily degrades hyaluronan, a naturally occurring glycosaminoglycan that can accumulate in the tumor microenvironment of certain solid tumors.

The HALO-301 study evaluated the addition of pegvorhyaluronidase alfa with gemcitabine and nab-paclitaxel (Abraxane, Celgene).

Researchers reported a higher overall response rate in the experimental treatment group, but there were no significant differences in duration of response, PFS or OS (11.2 months vs. 11.5 months; HR = 1) compared with gemcitabine and nab-paclitaxel alone.

“This well-designed and well-executed study did not have the outcome that we or the study participants wanted or expected,” Helen Torley, MB, ChB, MRCP, president and CEO of Halozyme, said in a company-issued press release.

“Patients in both treatment arms of the HALO-301 trial surpassed the published median overall survival rates from the pivotal registration study of Abraxane plus gemcitabine as first-line therapy for metastatic pancreas cancer, published in 2013,” Torley added. “Based on the lack of benefit over standard-of-care in this study, which performed well [compared with] published data, we will be discontinuing PEGPH20 clinical development.”